NASDAQ:HSGX - Histogenics Stock Price, Price Target & More

$2.67 -0.03 (-1.11 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$2.70
Today's Range$2.62 - $2.72
52-Week Range$1.59 - $3.35
Volume13,932 shs
Average Volume120,055 shs
Market Capitalization$76.88 million
P/E Ratio-2.76
Dividend YieldN/A
Beta1.69

About Histogenics (NASDAQ:HSGX)

Histogenics logoHistogenics Corporation, a regenerative medicine company, focuses on developing and commercializing products in the musculoskeletal segment of the marketplace in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900

Debt

Debt-to-Equity RatioN/A
Current Ratio2.15%
Quick Ratio2.15%

Price-To-Earnings

Trailing P/E Ratio-2.76
Forward P/E Ratio-3.93
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.46) per share
Price / Book-5.80

Profitability

EPS (Most Recent Fiscal Year)($0.98)
Net Income$-26,410,000.00
Net MarginsN/A
Return on Equity-658.91%
Return on Assets-131.87%

Miscellaneous

Employees45
Outstanding Shares28,690,000

How to Become a New Pot Stock Millionaire

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics' earnings last quarter?

Histogenics Corp. (NASDAQ:HSGX) issued its quarterly earnings data on Thursday, March, 15th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.05. View Histogenics' Earnings History.

When is Histogenics' next earnings date?

Histogenics is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Histogenics.

What price target have analysts set for HSGX?

2 Wall Street analysts have issued twelve-month price targets for Histogenics' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Histogenics' share price to reach $4.00 in the next twelve months. View Analyst Ratings for Histogenics.

Who are some of Histogenics' key competitors?

Who are Histogenics' key executives?

Histogenics' management team includes the folowing people:
  • Mr. Adam D. Gridley, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen R. Kennedy, COO & Exec. VP (Age 61)
  • Mr. Jonathan I. Lieber, Chief Financial Officer (Age 48)
  • Dr. Donald D. Haut Ph.D., Chief Bus. Officer
  • Mr. Peter Hamilton, VP of Operations & Engineering (Age 54)

When did Histogenics IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager.

Has Histogenics been receiving favorable news coverage?

Headlines about HSGX stock have trended somewhat positive on Wednesday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Histogenics earned a news impact score of 0.18 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.03 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $2.67.

How big of a company is Histogenics?

Histogenics has a market capitalization of $76.88 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]


MarketBeat Community Rating for Histogenics (HSGX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Histogenics (NASDAQ:HSGX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Histogenics in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 49.81%. The high price target for HSGX is $4.00 and the low price target for HSGX is $4.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$4.00
Price Target Upside: 49.81% upside36.05% upside94.17% upside123.11% upside

Histogenics (NASDAQ:HSGX) Consensus Price Target History

Price Target History for Histogenics (NASDAQ:HSGX)

Histogenics (NASDAQ:HSGX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018HC WainwrightReiterated RatingBuy$4.00MediumView Rating Details
12/21/2017Canaccord GenuityReiterated RatingBuy$4.00LowView Rating Details
9/19/2016Needham & Company LLCBoost Price TargetBuy$8.00 -> $11.00N/AView Rating Details
9/7/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
8/11/2016BTIG ResearchUpgradeNeutral -> Buy$3.50N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Histogenics (NASDAQ:HSGX) Earnings History and Estimates Chart

Earnings by Quarter for Histogenics (NASDAQ:HSGX)

Histogenics (NASDAQ:HSGX) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.69 EPS

Histogenics (NASDAQ HSGX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.25)N/AView Earnings Details
3/15/2018Q4 2017($0.31)($0.26)ViewListenView Earnings Details
11/9/2017Q3 2017($0.30)($0.23)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.31)($0.25)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.34)($0.27)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.47)($1.60)ViewN/AView Earnings Details
11/10/2016Q316($0.62)($0.70)ViewListenView Earnings Details
8/11/2016Q216($0.60)($0.61)ViewListenView Earnings Details
5/12/2016Q116($0.59)($0.60)ViewListenView Earnings Details
3/10/2016Q415($0.59)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.47)($0.61)ViewListenView Earnings Details
8/12/2015Q215($0.49)($0.58)ViewListenView Earnings Details
5/14/2015Q115($1.34)($0.60)ViewListenView Earnings Details
2/26/2015Q414$0.66$0.54ViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Histogenics (NASDAQ:HSGX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Histogenics (NASDAQ HSGX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 23.80%
Institutional Ownership Percentage: 42.96%
Insider Trading History for Histogenics (NASDAQ:HSGX)
Institutional Ownership by Quarter for Histogenics (NASDAQ:HSGX)

Histogenics (NASDAQ HSGX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2017David N GillDirectorBuy3,000$1.81$5,430.0014,000View SEC Filing  
5/16/2017David N GillDirectorBuy3,000$1.68$5,040.0011,000View SEC Filing  
12/15/2016David N GillDirectorBuy3,000$1.65$4,950.008,000View SEC Filing  
12/9/2016David N GillDirectorBuy5,000$1.92$9,600.005,000View SEC Filing  
12/2/2016Jonathan I LieberCFOBuy5,000$1.95$9,750.005,000View SEC Filing  
12/1/2016Adam GridleyInsiderBuy5,000$2.01$10,050.005,000View SEC Filing  
9/29/2016Split Rock Partners Ii, LpMajor ShareholderBuy276,801$2.25$622,802.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Histogenics (NASDAQ HSGX) News Headlines

Source:
DateHeadline
How Do Analysts See Histogenics Corporation (NASDAQ:HSGX) Performing Over The Next Few Years?How Do Analysts See Histogenics Corporation (NASDAQ:HSGX) Performing Over The Next Few Years?
finance.yahoo.com - April 19 at 9:27 AM
Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of DirectorsHistogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors
finance.yahoo.com - April 18 at 9:28 AM
Histogenics (HSGX) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowHistogenics (HSGX) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 11 at 4:29 PM
Histogenics (HSGX) Downgraded by ValuEngine to Strong SellHistogenics (HSGX) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - April 10 at 4:29 PM
Histogenics (HSGX) Rating Lowered to Hold at Zacks Investment ResearchHistogenics (HSGX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 9 at 4:05 PM
Histogenics (HSGX) Rating Increased to Sell at ValuEngineHistogenics (HSGX) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 3 at 1:55 PM
Histogenics (HSGX) Given "Buy" Rating at HC WainwrightHistogenics (HSGX) Given "Buy" Rating at HC Wainwright
www.americanbankingnews.com - April 1 at 11:24 PM
Histogenic (HSGX) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowHistogenic (HSGX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:28 PM
Histogenics (HSGX) Upgraded to "Sell" by ValuEngineHistogenics (HSGX) Upgraded to "Sell" by ValuEngine
www.americanbankingnews.com - March 25 at 5:24 PM
Histogenics (HSGX) Upgraded to Hold by Zacks Investment ResearchHistogenics (HSGX) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 24 at 8:55 PM
Analyzing Sangamo Therapeutics (SGMO) & Histogenics (HSGX)Analyzing Sangamo Therapeutics (SGMO) & Histogenics (HSGX)
www.americanbankingnews.com - March 20 at 2:06 PM
HC Wainwright Reaffirms Buy Rating for Histogenics (HSGX)HC Wainwright Reaffirms Buy Rating for Histogenics (HSGX)
www.americanbankingnews.com - March 19 at 10:58 AM
Histogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare ConferenceHistogenics Corporation to Present at Needham & Company’s 17th Annual Healthcare Conference
finance.yahoo.com - March 19 at 9:39 AM
Edited Transcript of HSGX earnings conference call or presentation 15-Mar-18 12:30pm GMTEdited Transcript of HSGX earnings conference call or presentation 15-Mar-18 12:30pm GMT
finance.yahoo.com - March 17 at 9:41 AM
Histogenics (HSGX) Presents At 38th Annual Cowen And Company Healthcare Conference - SlideshowHistogenics (HSGX) Presents At 38th Annual Cowen And Company Healthcare Conference - Slideshow
seekingalpha.com - March 15 at 4:57 PM
Histogenics (HSGX) Posts  Earnings Results, Beats Estimates By $0.05 EPSHistogenics (HSGX) Posts Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - March 15 at 1:39 PM
BRIEF-Histogenics Enters Equity Distribution DealBRIEF-Histogenics Enters Equity Distribution Deal
www.reuters.com - March 15 at 9:22 AM
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017
finance.yahoo.com - March 15 at 9:21 AM
Histogenics Corp. to Host Earnings CallHistogenics Corp. to Host Earnings Call
finance.yahoo.com - March 15 at 9:21 AM
Histogenics reports 4Q lossHistogenics reports 4Q loss
finance.yahoo.com - March 15 at 9:21 AM
Histogenics (HSGX) Stock Rating Upgraded by ValuEngineHistogenics (HSGX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 14 at 11:22 PM
Histogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual MeetingsHistogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings
finance.yahoo.com - March 10 at 9:36 AM
 Analysts Expect Histogenics Corp (HSGX) to Announce -$0.31 EPS Analysts Expect Histogenics Corp (HSGX) to Announce -$0.31 EPS
www.americanbankingnews.com - March 9 at 5:19 PM
Histogenics (HSGX) Scheduled to Post Earnings on ThursdayHistogenics (HSGX) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:10 AM
Histogenics (HSGX) Downgraded by ValuEngineHistogenics (HSGX) Downgraded by ValuEngine
www.americanbankingnews.com - March 4 at 5:00 PM
Histogenics Corporation to Report 2017 Financial Results on March 15, 2018Histogenics Corporation to Report 2017 Financial Results on March 15, 2018
feeds.benzinga.com - March 1 at 8:46 AM
Histogenics Corporation (NASDAQ:HSGX): Is Healthcare Attractive Relative To NasdaqCM Peers?Histogenics Corporation (NASDAQ:HSGX): Is Healthcare Attractive Relative To NasdaqCM Peers?
finance.yahoo.com - February 23 at 9:23 AM
Histogenics Corp (HSGX) Expected to Post Earnings of -$0.31 Per ShareHistogenics Corp (HSGX) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - February 20 at 11:14 PM
Histogenics Corporation to Present at Upcoming Investor ConferencesHistogenics Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - February 20 at 9:05 AM
Comparing Histogenics (HSGX) and Amicus Therapeutics (FOLD)Comparing Histogenics (HSGX) and Amicus Therapeutics (FOLD)
www.americanbankingnews.com - February 18 at 3:23 PM
Reviewing Pfizer (PFE) & Histogenics (HSGX)Reviewing Pfizer (PFE) & Histogenics (HSGX)
www.americanbankingnews.com - February 11 at 5:16 AM
Histogenics (HSGX) Rating Lowered to Sell at Zacks Investment ResearchHistogenics (HSGX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 28 at 10:52 PM
BRIEF-Perceptive Advisors LLC Reports 8.8 pct Passive Stake In Histogenics As Of Jan. 17BRIEF-Perceptive Advisors LLC Reports 8.8 pct Passive Stake In Histogenics As Of Jan. 17
www.reuters.com - January 26 at 4:25 PM
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesHistogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - January 25 at 4:25 PM
Histogenics (HSGX) Prices 2.34M Common Shares at $2.35/ShHistogenics (HSGX) Prices 2.34M Common Shares at $2.35/Sh
www.streetinsider.com - January 24 at 4:43 PM
Zacks: Brokerages Expect Histogenics Corp (HSGX) Will Announce Earnings of -$0.31 Per ShareZacks: Brokerages Expect Histogenics Corp (HSGX) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - January 18 at 1:42 AM
What Should You Know About Histogenics Corporation’s (NASDAQ:HSGX) Earnings Trajectory?What Should You Know About Histogenics Corporation’s (NASDAQ:HSGX) Earnings Trajectory?
finance.yahoo.com - January 10 at 11:30 AM
Histogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart AgreementHistogenics Corporation Announces Receipt of $10 Million Up-front Payment for Japanese Neocart Agreement
finance.yahoo.com - January 9 at 11:10 AM
Histogenics (HSGX) Lowered to "Hold" at Zacks Investment ResearchHistogenics (HSGX) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - December 28 at 11:42 PM
HC Wainwright Reiterates $4.00 Price Target for Histogenics (HSGX)HC Wainwright Reiterates $4.00 Price Target for Histogenics (HSGX)
www.americanbankingnews.com - December 28 at 10:14 PM
Histogenics (HSGX): HC Wainwright Sees The Japan Agreement As A Key Step for NeoCartHistogenics (HSGX): HC Wainwright Sees The Japan Agreement As A Key Step for NeoCart
www.streetinsider.com - December 28 at 4:29 PM
Comparing BioDelivery Sciences International (BDSI) & Histogenics (HSGX)Comparing BioDelivery Sciences International (BDSI) & Histogenics (HSGX)
www.americanbankingnews.com - December 24 at 8:05 AM
Histogenics (HSGX) Rating Reiterated by Canaccord GenuityHistogenics (HSGX) Rating Reiterated by Canaccord Genuity
www.americanbankingnews.com - December 22 at 1:38 PM
BRIEF-MEDINET signs license contract for NeoCart with HistogenicsBRIEF-MEDINET signs license contract for NeoCart with Histogenics
www.reuters.com - December 21 at 11:27 AM
Interested In Histogenics Corporation (NASDAQ:HSGX)? Here’s What Its Recent Track-Record Looks LikeInterested In Histogenics Corporation (NASDAQ:HSGX)? Here’s What Its Recent Track-Record Looks Like
finance.yahoo.com - December 15 at 11:54 AM
 Analysts Anticipate Histogenics Corporation (HSGX) Will Post Earnings of -$0.22 Per Share Analysts Anticipate Histogenics Corporation (HSGX) Will Post Earnings of -$0.22 Per Share
www.americanbankingnews.com - December 15 at 11:06 AM
-$0.22 EPS Expected for Histogenics Corporation (HSGX) This Quarter-$0.22 EPS Expected for Histogenics Corporation (HSGX) This Quarter
www.americanbankingnews.com - November 27 at 7:48 AM
Histogenics Corporation (HSGX) Rating Increased to Buy at Zacks Investment ResearchHistogenics Corporation (HSGX) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - November 25 at 9:32 AM
Histogenics Corporation (HSGX) Rating Reiterated by HC WainwrightHistogenics Corporation (HSGX) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 21 at 4:41 PM
Analyzing Histogenics Corporation (HSGX) and Innocoll Holdings PLC (INNL)Analyzing Histogenics Corporation (HSGX) and Innocoll Holdings PLC (INNL)
www.americanbankingnews.com - November 18 at 5:20 PM

SEC Filings

Histogenics (NASDAQ:HSGX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Histogenics (NASDAQ:HSGX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Histogenics (NASDAQ HSGX) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.